Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 2/2020

01-04-2020 | Prostate Cancer | Research Article

Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F] F and [18F]FDG: a Focus on Skeletal Lesions

Authors: Ida Sonni, Ryogo Minamimoto, Lucia Baratto, Sanjiv S. Gambhir, Andreas M. Loening, Shreyas S. Vasanawala, Andrei Iagaru

Published in: Molecular Imaging and Biology | Issue 2/2020

Login to get access

Abstract

Purpose

The purpose of this study is to prospectively evaluate the performance of sodium 18F]fluoride (Na[18F]F)/2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) simultaneous time-of-flight enabled positron emission tomography (PET)/magnetic resonance imaging (MRI) for the detection of skeletal metastases in selected patients with advanced breast and prostate cancers.

Procedure

The institutional review board approved this HIPAA-compliant protocol. Written informed consent was obtained from each patient. A total of 74 patients (23 women and 51 men with breast and prostate cancer, respectively) referred for standard-of-care whole-body bone scintigraphy (WBBS) were enrolled in this prospective study. All patients underwent a [99mTc]methyldiphosphonate ([99mTc]MDP) WBBS followed by Na[18F]F/[18F]FDG PET/MRI. Lesions detected by each imaging modality were tabulated and a lesion-based and patient-based analysis was conducted.

Results

On a patient-based analysis, [99mTc]MDP WBBS identified skeletal lesions in 37 patients and PET/MRI in 45 patients. On a lesion-based analysis, WBBS identified a total of 81 skeletal lesions, whereas PET/MRI identified 140 lesions. Additionally, PET/MRI showed extra-skeletal lesions in 19 patients, including lymph nodes (16), prostate (4) lung (3), and liver (2) lesions.

Conclusions

The ability of Na[18F]F/[18F]FDG PET/MRI to identify more skeletal lesions than 99mTc-MDP WBBS and to additionally identify extra-skeletal disease may be beneficial for patient care and represent an alternative to the single modalities performed separately. Na[18F]F/[18F]FDG PET/MRI is a promising approach for evaluation of skeletal and extra-skeletal lesions in a selected population of breast and prostate cancer patients.
Literature
1.
Even-Sapir E (2005) Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 46:1356–1367PubMed
2.
Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176CrossRef
3.
Van den Wyngaert T, Strobel K, Kampen T et al (2016) The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 43(1723):38
4.
Jacobson AF, Fogelman I (1998) Bone scanning in clinical oncology: does it have a future? Eur J Nucl Med Mol Imaging 25:1219–1223CrossRef
5.
Bombardieri E, Setti L, Kirienko M, Antunovic L, Guglielmo P, Ciocia G (2015) Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients? An open discussion. Q J Nucl Med Mol Imaging 59:381–399PubMed
6.
Czernin J, Satyamurthy N, Schiepers C (2010) Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med 51:1826–1829CrossRef
7.
Even-Sapir E, Metser U, Mishani E et al (2006) The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47:287–297PubMed
8.
Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, Mievis F, Aerts J, Waltregny D, Jerusalem G, Hustinx R (2011) 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 32:168–176CrossRef
9.
Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, Neumaier B, Träger H, Nüssle K, Reske SN (1999) Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 40:1623–1629PubMed
10.
Iagaru A, Mittra E, Dick DW, Gambhir SS (2012) Prospective evaluation of (99m)Tc MDP scintigraphy, 18F NaF PET/CT, and 18F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol 14:252–259CrossRef
11.
Shen CT, Qiu ZL, Han TT, Luo QY (2015) Performance of 18F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysis. Clin Nucl Med 40:103–110CrossRef
12.
Fogelman I, Cook G, Israel O, van der Wall H (2005) Positron emission tomography and bone metastases. Semin Nucl Med 35:135–142CrossRef
13.
Jadvar H (2009) Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. Nat Rev Urol 6:317–323CrossRef
14.
Meirelles GS, Schoder H, Ravizzini GC et al (2010) Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res 16:6093–6099CrossRef
15.
Iagaru A, Young P, Mittra E, Dick DW, Herfkens R, Gambhir SS (2013) Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Clin Nucl Med 38:e290–e296CrossRef
16.
Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML, Gambhir SS (2009) Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med 50:501–505CrossRef
17.
Lin FI, Rao JE, Mittra ES, Nallapareddy K, Chengapa A, Dick DW, Gambhir SS, Iagaru A (2012) Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy. Eur J Nucl Med Mol Imaging 39:262–270CrossRef
18.
Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, Iagaru A (2015) Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET/CT, and whole-body MRI in patients with breast and prostate Cancer. J Nucl Med 56:1862–1868CrossRef
19.
Sampath SC, Sampath SC, Mosci C, Lutz AM, Willmann JK, Mittra ES, Gambhir SS, Iagaru A (2015) Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone. Clin Nucl Med 40:e173–e177CrossRef
20.
Liu T, Cheng T, Xu W, Yan WL, Liu J, Yang HL (2011) A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skelet Radiol 40:523–531CrossRef
21.
Cook GJ, Azad G, Padhani AR (2016) Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. Clin Transl Imaging 4:439–447CrossRef
22.
Sotoudeh H, Sharma A, Fowler KJ, McConathy J, Dehdashti F (2016) Clinical application of PET/MRI in oncology. J Magn Reson Imaging 44:265–276CrossRef
23.
Mosavi F, Johansson S, Sandberg DT, Turesson I, Sörensen J, Ahlström H (2012) Whole-body diffusion-weighted MRI compared with 18F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol 199:1114–1120CrossRef
24.
Loening AM, Litwiller DV, Saranathan M, Vasanawala SS (2017) Increased speed and image quality for pelvic single-shot fast spin-Echo imaging with variable refocusing Flip angles and full-Fourier acquisition. Radiology 282:561–568CrossRef
25.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R (2015) Breast Cancer version 2.2015. J Natl Compr Cancer Netw 13:448–475CrossRef
26.
Groheux D (2018) Role of Fludeoxyglucose in Breast Cancer: Treatment Response. PET Clin 13:395–414CrossRef
27.
Jadvar H (2016) Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med 46(6):502–506CrossRef
28.
Eiber M, Holzapfel K, Ganter C, Epple K, Metz S, Geinitz H, Kübler H, Gaa J, Rummeny EJ, Beer AJ (2011) Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. J Magn Reson Imaging 33:1160–1170CrossRef
29.
Stecco A, Trisoglio A, Soligo E, Berardo S, Sukhovei L, Carriero A (2018) Whole-body MRI with diffusion-weighted imaging in bone metastases: a narrative review. Diagnostics (Basel) 8:45CrossRef
30.
Damle NA, Bal C, Bandopadhyaya GP, Kumar L, Kumar P, Malhotra A, Lata S (2013) The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol 31(4):262–269CrossRef
31.
Araz M, Aras G, Kucuk ON (2015) The role of 18F-NaF PET/CT in metastatic bone disease. J Bone Oncol 4:92–97CrossRef
32.
Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST (2008) Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 49:68–78CrossRef
33.
Iagaru A, Mittra E, Mosci C, Dick DW, Sathekge M, Prakash V, Iyer V, Lapa P, Isidoro J, de Lima JM, Gambhir SS (2013) Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. J Nucl Med 54:176–183CrossRef
34.
Grant AM, Deller TW, Khalighi MM, Maramraju SH, Delso G, Levin CS (2016) NEMA NU 2-2012 performance studies for the SiPM-based ToF-PET component of the GE SIGNA PET/MR system. Med Phys 43:2334–2343CrossRef
35.
Segall G, Delbeke D, Stabin M et al (2010) SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med 51:1813Y1820CrossRef
Metadata
Title
Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F] F and [18F]FDG: a Focus on Skeletal Lesions
Authors
Ida Sonni
Ryogo Minamimoto
Lucia Baratto
Sanjiv S. Gambhir
Andreas M. Loening
Shreyas S. Vasanawala
Andrei Iagaru
Publication date
01-04-2020
Publisher
Springer International Publishing
Published in
Molecular Imaging and Biology / Issue 2/2020
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-019-01392-9

Other articles of this Issue 2/2020

Molecular Imaging and Biology 2/2020 Go to the issue

Research Article

GABAA Receptors in the Mongolian Gerbil: a PET Study Using [18F]Flumazenil to Determine Receptor Binding in Young and Old Animals

Review Article

Quantitative Rodent Brain Receptor Imaging

Research Article

An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [18F]FP-(+)-DTBZ

Research Article

Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403

Special Topic

Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance

Research Article

Performance Evaluation of a Newly Developed MR-Compatible Mobile PET Scanner with Two Detector Layouts